HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Katlic, M. R. Articles by Grillo, H. C. Search for Related Content PubMed PubMed Citation Articles by Katlic, M. R. Articles by Grillo, H. C.

The Journal of Thoracic and Cardiovascular Surgery, Vol 99, 929-938, Copyright © 1990 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital

MR Katlic, EW Wilkins Jr and HC Grillo
General Thoracic Surgical Unit, Massachusetts General Hospital, Boston.

Seven hundred one patients with squamous cell carcinoma of the esophagus who were treated between 1950 and 1979 were retrospectively studied. The percentage of male patients decreased over the three decades (80% to 69%); the proportion of cigarette and alcohol abusers doubled. The esophageal carcinoma was located as follows: upper third, 24.7%; middle third, 52.8%, and lower third, 22.5%. There was disparity in clinical, surgical, and pathologic staging. More than two thirds of the patients thought to have stage II lesions preoperatively proved to have stage III lesions on pathologic examination; nearly one half of patients thought to have stage II disease intraoperatively were found to have pathologic stage III lesions. This "upgrading" of stage was chiefly a result of histologic recognition of nodal metastasis or extension of carcinoma into surrounding tissues. Operation was performed in 411 cases (58.6%) and resection was performed in 261 (37.2% overall). The postoperative death rate after resection fell from 30.5% in the 1950s to 10.4% in the 1970s, with respiratory complications the predominant cause of death. Analyses were based on treatment directed at the carcinoma itself: radiotherapy, 340 cases (48.5%); resection, 176 cases (25.1%); resection plus radiotherapy, 85 cases (12.1%); no definitive treatment, 100 cases (14.3%). Overall survival for the 701 patients was 13% at 2 years and 6% at 5 years (mean survival, 16.4 months); this did not differ by decade. Survival clearly differed by treatment (p = 0.001); resection plus radiotherapy provided the best survival (35% at 2 years; 20% at 5 years; mean of 32.5 months) followed by resection (18% at 2 years; 7% at 5 years; mean of 17.5 months), radiotherapy (9% at 2 years; 3% at 5 years; mean of 12.7 months), and no treatment (0% at 2 years; 0% at 5 years; mean of 2.5 months). Survival in patients who did not have resection did not differ by decade but survival in patients with resections improved in the last two decades. Patients with pathologic stage II lesions had greatly improved survival (54% at 2 years; 25% at 5 years; mean of 42.7 months) compared with patients with stage III disease (12% at 2 years; 6% at 5 years; (mean of 15.1 months) (p = 0.001).

This article has been cited by other articles:

				S. K. H. Wong, P. W. Y. Chiu, S. F. Leung, K. Y. Cheung, A. C. W. Chan, A. C. M. Au-Yeung, J. F. Griffith, S. S. C. Chung, and E. K. W. Ng Concurrent Chemoradiotherapy or Endoscopic Stenting for Advanced Squamous Cell Carcinoma of Esophagus: A Case-Control Study Ann. Surg. Oncol., February 1, 2008; 15(2): 576 - 582. [Abstract] [Full Text] [PDF]

				S. Y. Kang, J. H. Han, K. J. Lee, J.-H. Choi, J. I. Park, H. I. Kim, H.-W. Lee, J. H. Jang, J. S. Park, H. C. Kim, et al. Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy Clin. Cancer Res., July 15, 2007; 13(14): 4146 - 4153. [Abstract] [Full Text] [PDF]

				H. A. Wieder, B. L.D.M. Brucher, F. Zimmermann, K. Becker, F. Lordick, A. Beer, M. Schwaiger, U. Fink, J. R. Siewert, H. J. Stein, et al. Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment J. Clin. Oncol., March 1, 2004; 22(5): 900 - 908. [Abstract] [Full Text] [PDF]

				P. Flamen, E. Van Cutsem, A. Lerut, J.-P. Cambier, K. Haustermans, G. Bormans, P. De Leyn, D. Van Raemdonck, W. De Wever, N. Ectors, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer Ann. Onc., March 1, 2002; 13(3): 361 - 368. [Abstract] [Full Text] [PDF]

				J. B.F. Hulscher, J. G.P. Tijssen, H. Obertop, and J. J. B. van Lanschot Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis Ann. Thorac. Surg., July 1, 2001; 72(1): 306 - 313. [Abstract] [Full Text] [PDF]

				J. G. Brockmann, H. St. Nottberg, B. Glodny, A. Heinecke, and N. J. Senninger CYFRA 21-1 Serum Analysis in Patients with Esophageal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4249 - 4252. [Abstract] [Full Text] [PDF]

				H. Shiomi, Y. Eguchi, T. Tani, M. Kodama, and T. Hattori Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell Carcinoma Am. J. Pathol., February 1, 2000; 156(2): 567 - 575. [Abstract] [Full Text] [PDF]

				M. M. DeCamp Jr, S. J. Swanson, and M. T. Jaklitsch Esophagectomy After Induction Chemoradiation* Chest, December 1, 1999; 116(suppl_3): 466S - 469S. [Abstract] [Full Text] [PDF]